arsenic has been researched along with Peritoneal Neoplasms in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (33.33) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (66.67) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Han, K; Kang, CS; Kim, M; Kim, Y; Lee, EJ; Lim, J; Moon, Y; Pai, SH; Park, G | 1 |
Wang, B; Zhang, J | 1 |
Antoniello, L; Cohen, H; Fosman, E; Rodríguez, J; Rondán, M | 1 |
3 other study(ies) available for arsenic and Peritoneal Neoplasms
Article | Year |
---|---|
Arsenic trioxide (As2O3) sensitivity of carcinoma cell lines and cancer cells from patients with carcinomatosis peritonei.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma; Cell Line, Tumor; Cell Survival; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Oxides; Peritoneal Neoplasms; Xenograft Model Antitumor Assays | 2004 |
Arsenic trioxide (As(2)O(3)) inhibits peritoneal invasion of ovarian carcinoma cells in vitro and in vivo.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Adhesion; Cell Line, Tumor; Cell Movement; Dose-Response Relationship, Drug; Female; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Invasiveness; Ovarian Neoplasms; Oxides; Peritoneal Neoplasms; RNA, Messenger; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2 | 2006 |
[Hepato-splenic hemangiosarcoma: presentation of a clinical case].
Topics: Aged; Agricultural Workers' Diseases; Arsenic; Carcinoma, Hepatocellular; Colonic Neoplasms; Hemangiosarcoma; Humans; Liver Neoplasms; Male; Mesentery; Neoplasms, Multiple Primary; Omentum; Peritoneal Neoplasms; Splenic Neoplasms; Uruguay | 1989 |